Business
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
-First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim clinical update from Phase 1
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n-First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors-\n-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023-\n-$316.9 million in cash and cash equivalents and short-term investments at end of first quarter 2023-\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.\n\n\n“Janux hit a major milestone in the first quarter as we brought our second TRACTr program into a first-in-human clinical trial. We are excited for the potential for this EGFR-TRACTr to demonstrate the power of our technology and thereby address critical and urgent unmet needs for patients with advanced or metastatic solid tumors,” said David Campbell, Ph.D., President and CEO of Janux.\n\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\nJanux has prioritized its programs to enable sufficient funding to provide key clinical data assessments for its lead PSMA-TRACTr and EGFR-TRACTr programs.\n\n\n\nPSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in mCRPC.\n\n\n\n\nFirst patient dosed with EGFR-TRACTr program (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors.\n\n\n\n\nPD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.\n\n\n\n\nTROP2-TRACTr evaluations to support development candidate selection are ongoing.\n\n\n\nJanux anticipates providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023. In addition, Janux expects to select a development candidate for its TROP2-TRACTr in 2023.\n\n\nFIRST QUARTER 2023 FINANCIAL HIGHLIGHTS:\n\n\n\nCash and cash equivalents and short-term investments: As of March 31, 2023, Janux reported cash and cash equivalents and short-term investments of $316.9 million compared to $327.0 million at December 31, 2022.\n\n\n\n\nResearch and development expenses: Research and development expenses for the quarter ended March 31, 2023 were $15.9 million compared...